Deep Vein Thrombosis (DVT) is a potentially life-threatening condition that, if left untreated, can develop into pulmonary embolism or post-thrombotic syndrome. Early endovascular treatment of acute and subacute DVT can often mean better patient outcomes and long-term economic benefits.
The benefits of early endovascular treatment
Though anticoagulation and compression stockings remain the current standard of care for DVT, there is growing evidence that treating DVT as early as possible, particularly in high-risk cases of iliofemoral DVT, brings a host of benefits.
- Medication (anticoagulation and compression stockings) doesn’t remove the thrombus and can create complications down the road – making it harder and costlier to treat.
- Early thrombus removal is cost-efficient, with higher initial costs but proven long-term economic benefits1.
- During this phase, there are more treatment options available – mechanical, pharmacomechanical, CDT + lytics – all of them supported by Boston Scientific.
The risks of deep vein thrombosis
Clot management solutions: the confidence to choose
Effective clot management is fundamental to achieving beneficial and lasting clinical outcomes in the treatment of vascular disease. Boston Scientific is in the unique position of offering a highly differentiated solution for both pharmacomechanical and catheter-directed strategies, with proven benefits versus the standard of care.
AngioJet™ Ultra Peripheral Thrombectomy system
Angiojet is the only mechanical thrombectomy system with Power Pulse™ technology – giving you the option of adding lytic to your procedure when you encounter an organized clot.
This combination offers rapid and highly effective thrombus removal, and can often mean faster restoration of flow, reduced lytic needed and may shorten treatment time5.
Learn more about AngioJet >
AngioJet™ ZelanteDVT™ Thrombectomy Catheter
The AngioJet™ ZelanteDVT thrombectomy catheter is designed to treat DVT in large-diameter upper and lower peripheral veins. It removes 4X* the thrombus compared to earlier generations.
View the ZelanteDVT product page >
*When compared to current 6F AngioJet catheters. Bench test data on file.Bench test results may not necessarily be indicative of clinical performance
EKOS™ Endovascular System - ultrasound accelerated thrombolysis
Surgical thrombectomy was once the only option for patients with post-thrombotic damage, a complication of DVT. Studies show that the EKOS Endovascular System, which uses Acoustic Pulse Thrombolysis, is safe and effective for use in these patients.9
WALLSTENT™ Endoprosthesis
There is extensive evidence that WALLSTENT™ Endoprosthesis is safe and effective for the treatment of iliofemoral venous outflow obstruction. WALLSTENT is engineered to provide fracture resistance and withstand the forces common in venous anatomy.
Start your DVT training journey here
The BSC EDUCARE blended learning curriculum focuses on diagnostic and treatment strategies for deep vein thrombosis. It draws on the expertise and extensive experience of the foremost experts in the field.
- For existing EDUCARE users, access directly the full content.
- Still an unregistered user? Get an overview of the course to see what awaits you.
- Convinced? Proceed with EDUCARE registration by following the instructions depicted in this guide.
Format: 4 courses, covering 10 interactive modules.
Total time: 4 hrs and 45 minutes
References:
- Cost Effectiveness of Early Endovenous Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis in the United Kingdom, Joseph B. Babigumira, Stephen A. Black, Solomon J. Lubinga b, Anna L. Pouncey, Eur J Vasc Endovasc Surg (2024) 67, 490e498.
- Kahn S et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Annof Intern Med 2008;149(10):698-707.
- Sandler, D.A., et al., “Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?” J R Soc Med, 1989; 82: 203-5.
- Huisman, M.V., et al., “Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis.” Chest, 1989; 95(3): 498-502.
- Garcia MJ et al. Endovascular management of deep vein thrombosis with rheolytic thrombectomy: Final report of the prospective multicenter PEARL (Peripheral Use of AngioJet™ Rheolytic Thrombectomy with a Variety of Catheter Lengths) Registry. J Vasc Interv Radiol 2015;26(6):777-785.
- Tang T et al. Pharmacomechanical Tthrombectomy versus catheter-directed thrombolysis for iliofemoral deep vein thrombosis: A meta-analysis of clinical trials. Clin Appl Thromb Hemost. 2019;25:1-8.
- Pouncey AL et al. AngioJet™ Pharmacomechanical Thrombectomy and Catheter Directed Thrombolysis vs. Catheter Directed Thrombolysis Alone for the Treatment of Iliofemoral Deep Vein Thrombosis: A Single Centre Retrospective Cohort Study. Eur J Vasc Endovasc Surg 2020;60(4):578-585.
- Lichtenberg MKW et al. Endovascular mechanical thrombectomy versus thrombolysis in patients with iliofemoral deep vein thrombosis – a systematic review and meta-analysis. Vasa 2021;50(1):59-67.
- Garcia MJ et al. Ultrasound-accelerated thrombolysis and venoplasty for the treatment of post-thrombotic syndrome: Results of the ACCESS PTS Study. J Am Heart Assoc 2020;9(3):e013398.
Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.